Page 161 - HPP ANTIMICROBIAL GUIDELINE 2018
P. 161
Suggested Treatment
Infection/ Condition Comments
Preferred Alternative
Mycobacterial Infections
Hansen’s Disease (Leprosy)
(in non-HIV & HIV patient)
Paucibacillary Rifampicin 600mg PO monthly Bacterial resistance or hypersensitivity Remarks: Second line can
to first line only be initiated by a
PLUS Can be substituted with one of the dermatologist
Dapsone 100mg PO q24h following:
Duration: 6 months Ofloxacin 200mg PO q12h
(Completion of 6 doses within 9
months) PLUS
Surveillance: 5 years
Minocycline 100mg q24h
OR
Multibacillary Rifampicin 600mg PO monthly Clarithromycin 500mg PO q12h
OR
PLUS Ethionamide 250mg PO q24h
Clofazimine 300mg PO monthly
PLUS
Dapsone 100mg PO q24h
PLUS
Clofazimine 50mg PO q24h
Duration: 1 year (if initial BI˂4) or 18
months (if BI≥4)
Completion of 12 doses within 18
months (BI<4)
Completion of 18 doses within 24
months ( BI≥4)
Surveillance: 15 years
HPP AMG Skin & Soft Tissue Infections 75
